HIV with high CD4 count: early ART reduces risk for severe bacterial infections

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Immediate antiretroviral therapy (ART) reduces risk for a broad spectrum of severe bacterial infections in HIV-infected patients, and appears to be mediated partly by increases in CD4 cell count, but not neutrophils.

Why this matters

  • Effect of early ART on bacterial infections is important because these events are common in HIV-infected patients.

Key results

  • After median follow-up of 2.8 y, 120 of 4685 HIV-positive patients had severe bacterial infections (immediate-initiation group n=34, deferred-initiation group n=86).
  • Immediate vs deferred ART was associated with reduced risk for severe bacterial infection (HR, 0.39; P<.0001).
  • Average neutrophil and CD4 cell counts were 321.4 cells per μL and 194.2 cells per μL higher, respectively, in immediate- vs deferred-initiation groups (P<.0001).
  • On univariable analysis, higher time-updated CD4 cell count, but not neutrophil count was associated with reduced risk for severe bacterial infection.
  • After adjustment for time-updated CD4 cell count in multivariable models, HR for immediate-initiation group moved toward 1 (HR, 0.84; P=.52).

Study design

  • Preplanned secondary analysis of START to determine effects of immediate ART on all severe bacterial infections.
  • Funding: Various international government sources, including National Institutes of Health.

Limitations

  • Bacterial pneumonia and tuberculosis reported as main endpoints; few events limits study power.